3f3v: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
[[Image:3f3v.png|left|200px]] | [[Image:3f3v.png|left|200px]] | ||
{{STRUCTURE_3f3v| PDB=3f3v | SCENE= }} | {{STRUCTURE_3f3v| PDB=3f3v | SCENE= }} | ||
===Kinase domain of cSrc in complex with inhibitor RL45 (Type II)=== | ===Kinase domain of cSrc in complex with inhibitor RL45 (Type II)=== | ||
{{ABSTRACT_PUBMED_19462975}} | {{ABSTRACT_PUBMED_19462975}} | ||
==About this Structure== | ==About this Structure== | ||
[[3f3v]] is a 2 chain structure of [[Proto-oncogene tyrosine-protein kinase]] with sequence from [http://en.wikipedia.org/wiki/Gallus_gallus Gallus gallus]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=3F3V OCA]. | |||
==See Also== | |||
*[[Proto-oncogene tyrosine-protein kinase|Proto-oncogene tyrosine-protein kinase]] | |||
==Reference== | ==Reference== | ||
<ref group="xtra">PMID: | <ref group="xtra">PMID:019462975</ref><references group="xtra"/> | ||
[[Category: Gallus gallus]] | [[Category: Gallus gallus]] | ||
[[Category: Non-specific protein-tyrosine kinase]] | [[Category: Non-specific protein-tyrosine kinase]] | ||
| Line 31: | Line 22: | ||
[[Category: Rauh, D.]] | [[Category: Rauh, D.]] | ||
[[Category: Allosteric]] | [[Category: Allosteric]] | ||
[[Category: Atp-binding]] | [[Category: Atp-binding]] | ||
[[Category: Dfg-out]] | [[Category: Dfg-out]] | ||
| Line 45: | Line 35: | ||
[[Category: Type ii]] | [[Category: Type ii]] | ||
[[Category: Tyrosine-protein kinase]] | [[Category: Tyrosine-protein kinase]] | ||
Revision as of 15:52, 26 July 2012
Kinase domain of cSrc in complex with inhibitor RL45 (Type II)Kinase domain of cSrc in complex with inhibitor RL45 (Type II)
Template:ABSTRACT PUBMED 19462975
About this StructureAbout this Structure
3f3v is a 2 chain structure of Proto-oncogene tyrosine-protein kinase with sequence from Gallus gallus. Full crystallographic information is available from OCA.
See AlsoSee Also
ReferenceReference
- ↑ Getlik M, Grutter C, Simard JR, Kluter S, Rabiller M, Rode HB, Robubi A, Rauh D. Hybrid compound design to overcome the gatekeeper T338M mutation in cSrc. J Med Chem. 2009 Jul 9;52(13):3915-26. PMID:19462975 doi:10.1021/jm9002928